CytoDyn Inc  

(Public, OTCMKTS:CYDY)   Watch this stock  
Find more results for CYDY
-0.030 (-3.39%)
Mar 27 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 0.85 - 0.86
52 week 0.54 - 1.30
Open 0.86
Vol / Avg. 23,670.00/85,234.00
Mkt cap 50.22M
P/E     -
Div/yield     -
EPS -0.26
Shares 58.73M
Beta 2.52
Inst. own 0%

Key stats and ratios

Q4 (Nov '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -355.40% -197.56%
Return on average equity - -787.30%
Employees 3 -
CDP Score - -


United States - Map
+1-360-9808524 (Phone)

Website links


CytoDyn Inc. is a biotechnology company focused on discovering and developing a class of therapeutic monoclonal antibodies to treats Human Immunodeficiency Virus (HIV) infection. Its lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors. These therapies potentially block HIV from entering into and infecting certain cells. Although CytoDyn intends to focus its efforts on PRO 140, the Company also holds certain rights in two platform technologies: Cytolin, a monoclonal antibody targeting HIV with a mechanism of action which may prove to be synergistic to that of PRO 140 and other treatments, and CytoFeline, a monoclonal antibody targeting Feline Immunodeficiency Virus (FIV).

Officers and directors

Anthony D. Caracciolo Independent Chairman of the Board
Age: 59
Nader Z. Pourhassan Ph.D. President, Chief Executive Officer, Director
Age: 52
Michael D. Mulholland Chief Financial Officer, Treasurer, Corporate Secretary
Age: 62
Denis R. Burger Ph.D. Director
Age: 70
Carl Dockery Director
Gregory A. Gould CPA Independent Director
Age: 48
A. Bruce Montgomery M.D. Independent Director
Age: 60
Jordan G. Naydenov Independent Director
Age: 53